### ABOUT YOUR TREATMENT
You have been prescribed Lixiana®, an anticoagulant medicine, which thins your blood and helps prevent you from suffering blood clots. It is important that you take your medication exactly as instructed by your doctor.
- If you miss a dose, take it immediately and then continue the following day as normal – do not take double the prescribed dose in a single day.
- Do not start any other medications (including over the counter) without consulting your doctor.
- Do not stop taking Lixiana® without consulting your doctor as this can increase your risk of developing a blood clot.
- Please read the Patient Information Leaflet found inside each pack of Lixiana®.

### WHEN TO SEEK MEDICAL ADVICE
**RISK OF BLEEDING**
Taking an anticoagulant medicine such as Lixiana® can increase your risk of bleeding. It is therefore important to be aware of the possible signs and symptoms of bleeding and to speak to your doctor immediately if you experience any of the following:
- Bruising or bleeding under the skin
- Blood in the urine
- Coughing up blood
- Vomiting blood or material that looks like ground coffee
- Nose bleeds or cuts that take a long time to stop bleeding
- Tar-coloured stools
- Dizziness or sudden headache
- Unexplained tiredness
- Abnormal vaginal bleeding, including heavier or prolonged menses
Please talk to your doctor if you experience any unusual symptoms.

### TREATMENT INFORMATION
(To be completed by physician)
Lixiana® has been prescribed at a once-daily dose of: .......... mg
Started on: / (mm/yy)
Blood type: ......................
Other medications/conditions:

---

### PRESCRIBER INFORMATION
For more information or in case of emergency, please contact:
Physician’s name:

..................................................
Phone number, practice stamp:

..................................................
Signature of physician:

..................................................

### INFORMATION FOR HEALTHCARE PROFESSIONALS
- Lixiana® is an oral anticoagulant factor Xa inhibitor.
- When an invasive procedure is required, Lixiana® should be stopped at least 24 hours beforehand, and appropriate caution exercised.
- Lixiana® may increase the risk of bleeding. In case of clinically significant bleeding, stop treatment immediately.
- Coagulation tests such as INR, prothrombin time (PT), or activated partial thromboplastin time (aPTT) are not a useful measure of the effect of Lixiana®. However, a calibrated anti-Factor Xa assay may help inform clinical decisions.

Please consult the Summary of Product Characteristics (SmPC) for more information.